Bombesin
[Pyr]-QRLGNQWAVGHLM-amide
Description
Application Data
Description
-
Bombesin is a widely expressed in the CNS and GI tract and has a wide range of physiological functions; contains N-terminal pyroglutamyl.
Application Data
-
Catalogue number crb1000583 Molecular Weight 1618.8 Sequence (one letter code) [Pyr]-QRLGNQWAVGHLM-amide
Sequence (three letter code) [Pyr]-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
Modifications where Pyr is pyroglutamyl Purity >95% cas 31362-50-2 Storage -20°C Citations Harti et al., (1989). Effects of capsaicin in rat and pigeon on peripheral nerves containing substance P and calcitonin gene-related peptide. Cell Tissue Res. 256(3): 465. doi: 10.1007/BF00225594.
References Shimizu et al (2016) A Stress-Related Peptide Bombesin Centrally Induces Frequent Urination through Brain Bombesin Receptor Types 1 and 2 in the Rat. J. Pharmacol. Exp. Ther. 356(3) 693 PMID: 26729307
Sancho et al (2011) Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status. Curr. Drug Deliv. 8(1) 79 PMID: 21034419
Manufactured in: United Kingdom Bombesin was originally isolated from the skin of the European fire-bellied toad (Bombina bombina) and has two known homologues in mammals; neuromedin B (NMB) and gastrin-releasing peptide (GRP).
Bombesin-like peptides are involved in many physiological functions including: regulation of food intake; anxiety and fear–related behaviour; thermoregulation; stress response; learning and memory and in the stimulation of smooth muscle contraction. Bombesin is also a tumour marker for small cell carcinoma in the lung; gastric cancer; pancreatic cancer, and neuroblastoma.
The receptors for these two peptides are G-protein-coupled receptors known as bombesin receptor type 1 (BB1; also known as NMB receptor) and bombesin receptor type 2 (BB2; also known as GRP- receptor). Bombesin shows high affinity to both of these receptor subtypes. These bombesin-like peptides and their receptors are widely distributed in the central nervous system (CNS) and gastrointestinal (GI) tract.
This peptide contains an N-terminal pyroglutamyl to prevent the intramolecular cyclisation of the N-terminal of glutamine to N‐pyroglutamate (pGlu).